Integra LifeSciences (IART) Q4 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Earnings

Integra LifeSciences navigated a turbulent quarter with a modest beat on both top and bottom lines, though the underlying results painted a more complicated picture. The medical device maker posted Q4 2025 adjusted EPS of $0.83, ahead of the $0.80 co… Read more Integra LifeSciences navigated a turbulent quarter with a modest beat on both top and bottom lines, though the underlying results painted a more complicated picture. The medical device maker posted Q4 2025 adjusted EPS of $0.83, ahead of the $0.80 consensus estimate by 3.72%, while revenue of $434.93 million edged past expectations by 1.23%, even as sales slipped 1.7% year over year. The headline beat masked meaningful divergence across the business: Codman Specialty Surgical, representing roughly three-quarters of total revenue, grew 2.7% on a reported basis, driven by double-digit gains in CereLink and Mayfield capital products, while Tissue Technologies fell 12.8%, dragged lower by a 21.4% organic decline in Wound Reconstruction tied largely to MediHoney remediation efforts. The company's stock came under pressure following the release, reflecting investor unease over a full-year GAAP net loss of $516.47 million, heavy debt at 4.5x leverage, and a weakening cash flow profile. Looking ahead, Integra guided 2026 revenues to $1.66 billion to $1.70 billion with adjusted EPS of $2.30 to $2.40, as a newly simplified operating model is expected to deliver $25 million to $30 million in savings.